STOCK TITAN

Evommune reprices director McGraw’s stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Evommune, Inc. director Benjamin F. McGraw III reported a one-time option repricing on November 13, 2026: 37,960 options with a $16 exercise price and 15,673 options with a $19.82 exercise price were deemed canceled and replaced with options at $7.63 per share. If exercised before the earlier of November 13, 2027 and a Change in Control during his Continuous Service, the premium exercise price is the original exercise price for each option.

The 37,960-option award was one-third vested on November 5, 2026, with the remainder vesting in 24 equal monthly installments, subject to continuous service. The 15,673-option award vests on the earlier of June 2, 2027 and the next annual meeting, also subject to continuous service.

Insider MCGRAW BENJAMIN F III
Role Director
Type Security Shares Price Value
Disposition Stock Option (Right to buy) F1, F2, F3 37,960 -- --
Grant/Award Stock Option (Right to buy) F1, F2, F3 37,960 -- --
Disposition Stock Option (Right to buy) F4, F2, F5 15,673 -- --
Grant/Award Stock Option (Right to buy) F4, F2, F5 15,673 -- --
Holdings After Transaction: Stock Option (Right to buy) — 53,633 options (Direct)
Holdings Before and After: Stock Option (Right to buy), 53,633 to 53,633 options (Direct)
Footnotes (5)
  1. F1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
  2. F2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; and (ii) a Change in Control during the Reporting Person's Continuous Service, each as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
  3. F3. One third (1/3) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
  4. F4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 2, 2026.
  5. F5. The shares subject to the option award shall vest at the earlier of (i) June 2, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Options repriced 37,960 options Options with a $16 exercise price were deemed canceled and replaced on November 13, 2026.
Original exercise price $16 per share Exercise price for the 37,960 options deemed canceled.
Options repriced 15,673 options Options with a $19.82 exercise price were deemed canceled and replaced on November 13, 2026.
Original exercise price $19.82 per share Exercise price for the 15,673 options deemed canceled.
Replacement exercise price $7.63 per share Exercise price for the replacement options, subject to the stated premium exercise price condition.
Option Repricing technical
"the one-time stock option repricing"
premium exercise price technical
"required to pay a premium exercise price equal to the original exercise price"
Change in Control technical
"a Change in Control during the Reporting Person's Continuous Service"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Continuous Service technical
"during the Reporting Person's Continuous Service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What options did Evommune (EVMN) director Benjamin F. McGraw III reprice?

On November 13, 2026, 37,960 options with a $16 exercise price and 15,673 options with a $19.82 exercise price were deemed canceled and replaced with options at $7.63 per share. The transactions were described as a one-time stock option repricing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MCGRAW BENJAMIN F III

(Last)(First)(Middle)
C/O EVOMMUNE, INC.
1891 PAGE MILL ROAD

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$1611/13/2026D(1)37,960 (3)11/04/2035Common Stock37,960(2)0.00D
Stock Option (Right to buy)$7.6311/13/2026A(1)37,960 (3)11/04/2035Common Stock37,960(2)37,960D
Stock Option (Right to buy)$19.8211/13/2026D(4)15,673 (5)06/01/2036Common Stock15,673(2)0.00D
Stock Option (Right to buy)$7.6311/13/2026A(4)15,673 (5)06/01/2036Common Stock15,673(2)15,673D
Explanation of Responses:
1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; and (ii) a Change in Control during the Reporting Person's Continuous Service, each as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
3. One third (1/3) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 2, 2026.
5. The shares subject to the option award shall vest at the earlier of (i) June 2, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Remarks:
/s/ Gregory S. Moss, Attorney-in-Fact11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading